Merus Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for Plenary Session Oral Presentation at the AACR Annual Meeting 2023 and Provides a Program and Regulatory Update

(marketscreener.com) - Robust 36% overall response rate in 42 evaluable patients - 6 months median duration of response with 17 patients still on treatment as of Nov. 28, 2022 data cutoff - End-of-Phase meeting with U.S. Food & Drug Administration provides clarity to potential registration path in HNSCC - Investor call on April 17, 2023 at 6:30 p.m. ET ET...https://www.marketscreener.com/quote/stock/MERUS-N-V-27548017/news/Merus-Announces-Publication-of-an-Abstract-on-Petosemtamab-Monotherapy-in-Previously-Treated-Head-an-43497069/?utm_medium=RSS&utm_content=20230414